WCN26-5702 The Effect of Etelcalcetide on Uncontrolled Secondary Hyperparathyroidism Among Hemodialysis Patients- Single Centre Experience

Read full text Summarise with VIRAT
Authors: Ihab El Madhoun, Rony Jose Pulikkan, Ahmed Emam, Mourad Bouarour, Shibu Jacob, Krishnakumar Karipoth, Ma Lisette Lucina Canapi, Amna Mohamed Ahmed, Jyothy Karimattathil Joseph, Divya Mahilamani
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Secondary hyperparathyroidism (sHPT) is a common complication of chronic kidney disease and characterized by elevated intact serum parathyroid hormone (iPTH). Etelcalcetide is an intravenous calcimimetic that increases the sensitivity of the calcium-sensing receptor to calcium and decreases PTH secretion. Many dialysis patients have uncontrolled hyperparathyroidism despite using Calcium supplements, vitamin D analogs & oral calcimimetics (Cinacalcet). Etelcalcetide is a novel intravenous calcimimetic used for the treatment of secondary hyperparathyroidism in dialysis patients1 which has fewer Gastrointestinal (GI) side effects compared to oral calcimimetic.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Potassium and Related Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105002–105002
Publication date
25 March 2026
Language
EN